Target-volume model predicted HyTEC-based SRS prescriptions before plan generation
A model using target volume and HyTEC limits estimated automated SRS prescription doses with approximately 1.3% mean absolute error.
Tag
SRS
Memantine preserved cognition after radiotherapy for brain metastases in randomized trial
Memantine preserved 6-month cognition versus placebo after radiotherapy for brain metastases, with benefits also seen in quality of life.
Higher LINAC SRS dose rate was linked to longer pain control in trigeminal neuralgia
Treatment failure at one year was 14.4% at 2400 MU/min versus 42.7% at 800 MU/min, with similar facial numbness.
SRS target location changed pain-response patterns in trigeminal neuralgia
Distal targeting produced more overall pain relief, while proximal targeting yielded more complete pain freedom and medication discontinuation.
Enhanced MLC modeling did not outperform optimized DLG modeling for single-isocenter SRS
Enhanced leaf and optimized DLG models produced similarly accurate SRS dose calculations, with DLG showing a small QA advantage.
Cystic vestibular schwannomas shrank earlier after SRS than solid tumors
Large cystic Koos III–IV vestibular schwannomas showed greater early shrinkage after SRS, with 100% local control in 15 cystic cases.
Repeat stereotactic radiotherapy achieved 76% one-year local control for recurrent brain metastases
Across 14 studies, repeat stereotactic radiotherapy achieved 76% one-year local control, but symptomatic radiation necrosis occurred in 10%.
Environ SRS mask reduced attenuation and vertical setup variability versus Encompass
Environ showed less static-beam attenuation and lower vertical setup variability than Encompass while maintaining accurate HyperArc dose calculation.
Gamma Knife and LINAC radiosurgery produced similar vestibular schwannoma outcomes
Gamma Knife and LINAC radiosurgery produced similarly high control and low new neurologic symptoms in 85 vestibular schwannoma patients.
KRAS mutation did not worsen intracranial control after SRS for NSCLC brain metastases
KRAS-mutant and wild-type NSCLC showed similar intracranial control after SRS, while higher radiation dose predicted better outcomes.
SMART planning reduced memory-circuit dose during SRS for ≥10 brain metastases
SMART reduced mean memory-circuit dose from 2.9 to 1.8 Gy while maintaining greater than 95% target coverage.
Brain metastasis SRS fractionation varied widely across Turkish radiation oncologists
Tumor volume and OAR proximity drove brain metastasis fractionation, while preoperative SRS showed a substantial preference-to-practice gap.
SRT did not improve survival over whole-brain radiotherapy after matching in SCLC
After propensity matching, SRT did not improve survival over WBRT, while adding a boost showed a non-robust intracranial control signal.
Brainlab reference beam model enabled one-day SRS commissioning with accurate Monte Carlo calculations
Brainlab Elements commissioning was completed in one day, while Monte Carlo generally agreed with end-to-end measurements within 3%.
ESTRO review supports selective CNS reirradiation but highlights cumulative-dose limits
ESTRO supports individualized reirradiation for selected recurrent brain tumors, with cumulative dose, target volume and critical structures determining feasibility.